0
Cantargia publishes interim report for first quarter 2021
Cantargia AB's ("Cantargia") interim report for first quarter 2021 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the first quarter
The first patient with pancreatic cancer started treatment in the extension part of the CANFOUR study.
An application was submitted to start a new phase Ib clinical study on combination treatment with CAN04 and FOLFIRINOX in pancreatic cancer.
Positive preclinical safety and efficacy results were presented for the CAN10 antibody.
Significant events after the end of the period
Preclinical results for the CAN10 antibody were presented at the IMMUNOLOGY2021 conference.
A letter of intent was signed with GEICAM to conduct a clinical study with CAN04 in combination with carboplatin/gemcitabine in triple negative breast cancer.
Positive interim results were presented from the CANFOUR study showing an improved progression-free survival and overall survival for combination treatment with CAN04 and chemotherapy in pancreatic cancer, compared to historical control data.
Financial information
First Quarter 2021
Net sales: SEK 0 (0) million
Operating loss: SEK -73.2 (-39.9) million
Loss after tax: SEK -72.6 (-40.0) million
Loss per share: before and after dilution, SEK -0.72 (-0.49)
Equity/assets ratio: 94 (95) per cent
Cash and cash equivalents: SEK 176.4 (237.2) million
Short-term investments: SEK 666.0 (259.6) million
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]
Cantargia AB's ("Cantargia") interim report for first quarter 2021 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the first quarter
The first patient with pancreatic cancer started treatment in the extension part of the CANFOUR study.
An application was submitted to start a new phase Ib clinical study on combination treatment with CAN04 and FOLFIRINOX in pancreatic cancer.
Positive preclinical safety and efficacy results were presented for the CAN10 antibody.
Significant events after the end of the period
Preclinical results for the CAN10 antibody were presented at the IMMUNOLOGY2021 conference.
A letter of intent was signed with GEICAM to conduct a clinical study with CAN04 in combination with carboplatin/gemcitabine in triple negative breast cancer.
Positive interim results were presented from the CANFOUR study showing an improved progression-free survival and overall survival for combination treatment with CAN04 and chemotherapy in pancreatic cancer, compared to historical control data.
Financial information
First Quarter 2021
Net sales: SEK 0 (0) million
Operating loss: SEK -73.2 (-39.9) million
Loss after tax: SEK -72.6 (-40.0) million
Loss per share: before and after dilution, SEK -0.72 (-0.49)
Equity/assets ratio: 94 (95) per cent
Cash and cash equivalents: SEK 176.4 (237.2) million
Short-term investments: SEK 666.0 (259.6) million
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]
